Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Stressgen Phase II RRP results

Stressgen (TSE:SSB) said in a Phase II trial in 27 pediatric patients with recurrent respiratory papillomatosis (RRP), its HspE7 significantly

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE